Aortech Share Discussion Threads

[the stigologist] 11/12/2017 12:06

MMs going to have to gap this up to 100p as the market wakes up to the potential here

[the stigologist] 11/12/2017 12:06

Why compete with their own customers ?

Simply be a neutral arms supplier to others in the arms race. Like the picks and shovel sellers in the gold rush.

If your current licensees aren't paying you enough, don't compete with them, threaten to provide or provide their competitors with your technology as well (assuming there is no exclusivity in place)

[landy90] 11/12/2017 12:01

Reading Between the Lines..

“Our licensees have generated considerable value by utilising Elast-Eon™. One example of this is a cardiovascular device that differs only from competing devices by having a thin Elast-Eon™ coating. This coating provides the device with superior properties and allows a sales price of many multiples of standard devices. The cost of materials and license fees, however, are less than 5% of the device’s sales value.”

There is much more to gain from owning devices enabled by ElastEon than selling polymer.


“The Board has conducted a thorough review of the Company’s IP and where it fits into the medical device market, leading to the conclusion that there are a number of opportunities available to grow AorTech’s business.”

A number of devices have been identified that would be better if they used ElastEon



“A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded.”



They are working on a plan to take the company up the value chain.

[deanmatlazin] 11/12/2017 11:52

It is very undervalued with tiny market cap. A ten bagger for me at this price.

[semper vigilans] 11/12/2017 11:48

Yes Stig - hopefully conservative figs used too. This is without any ‘hidden bonus’ that may come from the settlement.

[brucie5] 11/12/2017 11:37

You have your uses, Stig.
😉

[the stigologist] 11/12/2017 11:27

For those who care by my calcs Half Yearly breakdown like this

Period H1 FY2017 H2 FY2017 H1FY2018

Revenue $240k $374k $271k
Admin $349k $222k $239k
Profit ($110k) $152k $32k

[the stigologist] 11/12/2017 11:26

I've just been looking at the Half Yearly breakdowns.

If we repeat last year H2 we're looking at a Trading Profit for this year of c.$200k

Put that on a 'normal' growth/recovery PE and you're looking at 20x $200k = $4m Mkt Cap

Put it on an ARM type royalty/licencing PE of 50-100x and you're looking at $10-20m Mkt Cap

The Market is totally behind the curve with this one.

I was in PYC (and still am) from 1p to 30p recently and this looks exactly like that in terms of an upcoming multi-day multi-bag re-rating

[k1ngkonggb] 11/12/2017 11:16

Investor,

They probably bought in at an earlier price this morning and want a quick killing. Welcome to the world of day traders...a quick £50 or £100 !!!

MM's need the shares as the amount in circulation are tightly held so what better way than to drop the price as well. I still think we will see it strengthen in the afternoon and by Chrimbo, probably not far off £1.

IMHO

[mikeh30] 11/12/2017 11:14

The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.

[investordave] 11/12/2017 11:09

I can't believe so many people are rushing to still at this price.

[mikeh30] 11/12/2017 11:08

Easy £10m cap. They even stated in the interims it was priced to go bust

[the stigologist] 11/12/2017 11:06

I'm really trying to be conservative but this is worth MULTIPLES of current Market Cap

[mikeh30] 11/12/2017 10:57

Mr 9108 held for a full 58 minutes then sold for a loss. Cok* and hoo*ers fund increasing for this years xmas party

[mikeh30] 11/12/2017 10:46

Didn't this use to trade at around 1000p per share? Granted only 3m shares in issue back then compared to 5m now.

[the stigologist] 11/12/2017 10:32

the intraday consolidation reminiscent of PYC between 1p and 2p

[deanmatlazin] 11/12/2017 10:30

Our licensees have generated considerable value by utilising Elast-Eon(TM). One example of this is a cardiovascular device that differs only from competing devices by having a thin Elast-Eon(TM) coating. This coating provides the device with superior properties and allows a sales price of many multiples of standard devices. The cost of materials and license fees, however, are less than 5% of the device's sales value.

The value added to licensees is not only greater than licence fees payable, but the value of the licence fees to our customers is significantly more than the market capitalisation of AorTech


The above statement make me think this is going to go up like PYC. Fingers crossed.

[the stigologist] 11/12/2017 10:25

and should be fatter

[luckymouse] 11/12/2017 10:21

fat margins

[the stigologist] 11/12/2017 10:08

ten bagger in weeks not months i reckon

break 40p we gap to 100p

[yuletea] 11/12/2017 10:08

The spike bar chat is Eddie McDaid wants to kick Bill off the Board because he turned down a 90% dilution proposal at 10p a share.

[deanmatlazin] 11/12/2017 10:04

Buy and hold. I am looking for a ten bagger in next 12 months. I think this is one of them.

[the stigologist] 11/12/2017 10:00

AOR

This makes for such good reading :-

'Multiples'!



Our licensees have generated considerable value by utilising Elast-Eon(TM). One example of this is a cardiovascular device that differs only from competing devices by having a thin Elast-Eon(TM) coating. This coating provides the device with superior properties and allows a sales price of many multiples of standard devices. The cost of materials and license fees, however, are less than 5% of the device's sales value.

The value added to licensees is not only greater than licence fees payable, but the value of the licence fees to our customers is significantly more than the market capitalisation of AorTech

The Board has conducted a thorough review of the Company's IP and where it fits into the medical device market, leading to the conclusion that there are a number of opportunities available to grow AorTech's business. A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded.

We have the opportunity of putting past issues behind us and building on the core IP within the business. As part of this "fresh start", I am delighted to welcome Stockdale Securities as our new Nominated Adviser and broker and look forward to working with them to help AorTech reach its true potential.